Translational research insights into pharmacokinetic herb-drug interactions

Current Drug Metabolism

Volumn 12, Issue 9, 2011, Pages 850-870

  Hao, Haiping ^a   Zheng, Xiao ^a   Li, Ping ^a   Wang, Guangji ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Cytochrome P450; Herb drug interactions; Pharmacokinetics; Translational blocks.; Translational research

Indexed keywords

ALLICIN; ALLIIN; BERBERINE; CATECHIN; CICHORIC ACID; CRYPTOTANSHINONE; DESMETHOXYYANGONIN; DIHYDROMETHYSTICIN; ECHINACEA PURPUREA EXTRACT; ECHINACOSIDE; GINKGO BILOBA EXTRACT; GINKGOLIDE; GINSENOSIDE; HERBACEOUS AGENT; HYDRASTINE; HYPERFORIN; KAEMPFEROL; KAWAIN; METHYSTICIN; MIDAZOLAM; PLANT EXTRACT; QUERCETIN; SAQUINAVIR; SILIBININ; SILICRISTIN; SILIDIANIN; TANSHINONE I; TANSHINONE IIA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALEPOTRIATE;

DRUG EFFECT; DRUG ELIMINATION; DRUG INHIBITION; DRUG METABOLISM; ENZYME ACTIVITY; GENOTYPE; HERB DRUG INTERACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; REVIEW; TRANSLATIONAL RESEARCH;

EID: 80053477457     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920011797470155     Document Type: Review

References (279)

1. Zhou, S.F.; Xue, C.C.; Yu, X.Q.; Wang, G. Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications, an update. Curr. Drug Metab., 2007, 8(6), 526-553. (Pubitemid 47209094)
2. Jha, V. Herbal medicines and chronic kidney disease. Nephrology (Carlton), 2010, 15 Suppl 2, 10-17.
3. Zhang, L.; Wang, G.; Hou, W.; Li, P.; Dulin, A.; Bonkovsky, H.L. Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China, an analytical review. Hepatology, 2010, 51(2), 690-698.
4. Wang, C.Z.; Mehendale, S.R.; Yuan, C.S. Commonly used antioxidant botanicals, active constituents and their potential role in cardiovascular illness. Am. J. Chin. Med., 2007, 35(4), 543-558. (Pubitemid 47307694)
5. Bent, S. Herbal medicine in the United States, review of efficacy, safety, and regulation, grand rounds at University of California, San Francisco Medical Center. J. Gen. Intern. Med., 2008, 23(6), 854-859.
6. Yang, A.K.; He, S.M.; Liu, L.; Liu, J.P.; Wei, M.Q.; Zhou, S.F. Herbal interactions with anticancer drugs, mechanistic and clinical considerations. Curr. Med. Chem., 2010, 17(16), 1635-1678.
7. Kennedy, D.A.; Seely, D. Clinically based evidence of drug-herb interactions, a systematic review. Expert Opin. Drug Saf., 2010, 9(1), 79-124.
8. Butterweck, V.; Derendorf, H.; Gaus, W.; Nahrstedt, A.; Schulz, V.; Unger, M. Pharmacokinetic herb-drug interactions, are preventive screenings necessary and appropriate? Planta Med., 2004, 70(9), 784-791. (Pubitemid 39361743)
9. Abad, M.J.; Bedoya, L.M.; Bermejo, P. An update on drug interactions with the herbal medicine Ginkgo biloba. Curr. Drug Metab., 2010, 11(2), 171-181.
10. Izzo, A.A.; Ernst, E. Interactions between herbal medicines and prescribed drugs, a systematic review. Drugs, 2001, 61(15), 2163-2175. (Pubitemid 34074799)
11. Izzo, A.A.; Ernst, E. Interactions between herbal medicines and prescribed drugs, an updated systematic review. Drugs, 2009, 69(13), 1777-1798.
12. Tarirai, C.; Viljoen, A.M.; Hamman, J.H. Herb-drug pharmacokinetic interactions reviewed. Expert Opin. Drug Metab. Toxicol., 2010, 6(12), 1515-1538.
13. Vlachojannis, J.; Cameron, M.; Chrubasik, S. Drug interactions with St. John's wort products. Pharmacol. Res., 2010.
14. Butterweck, V.; Derendorf, H. Potential of pharmacokinetic profiling for detecting herbal interactions with drugs. Clin. Pharmacokinet., 2008, 47(6), 383-397. (Pubitemid 351685388)
15. Nowack, R.; Andrassy, J.; Fischereder, M.; Unger, M. Effects of dietary factors on drug transport and metabolism, the impact on dosage guidelines in transplant patients. Clin. Pharmacol. Ther., 2009, 85(4), 439-443.
16. Fitzgerald, G.A. Opinion, anticipating change in drug development, the emerging era of translational medicine and therapeutics. Nat. Rev. Drug. Discov., 2005, 4(10), 815-818.
17. Lauer, M.S.; Skarlatos, S. Translational research for cardiovascular diseases at the National Heart, Lung, and Blood Institute, moving from bench to bedside and from bedside to community. Circulation, 2010, 121(7), 929-933.
18. Wang, P.S.; Heinssen, R.; Oliveri, M.; Wagner, A.; Goodman, W. Bridging bench and practice, translational research for schizophrenia and other psychotic disorders. Neuropsychopharmacology, 2009, 34(1), 204-212.
19. Paterson, N.E. Translational research in addiction, Toward a framework for the development of novel therapeutics. Biochem. Pharmacol., 2011.
20. Simon, R. Translational research in oncology, key bottlenecks and new paradigms. Expert Rev. Mol. Med., 2010, 12, e32.
21. Von Herrath, M.; Chan, A. How can we improve the translational landscape for a faster cure of type 1 diabetes? J. Clin. Invest., 2009, 119(5), 1061-1065.
22. Williamson, E.M. Drug interactions between herbal and prescription medicines. Drug Saf., 2003, 26(15), 1075-1092. (Pubitemid 38021390)
23. Breidenbach, T.; Hoffmann, M.W.; Becker, T.; Schlitt, H.; Klempnauer, J. Drug interaction of St John's wort with cyclosporin. Lancet, 2000, 355(9218), 1912. (Pubitemid 30311894)
24. Ruschitzka, F.; Meier, P.J.; Turina, M.; Luscher, T.F.; Noll, G. Acute heart transplant rejection due to Saint John's wort. Lancet, 2000, 355(9203), 548-549. (Pubitemid 30088678)
25. Chatterjee, P.; Franklin, M.R. Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab. Dispos., 2003, 31(11), 1391-1397. (Pubitemid 37310329)
26. Gurley, B.J.; Gardner, S.F.; Hubbard, M.A.; Williams, D.K.; Gentry, W.B.; Khan, I.A.; Shah, A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin. Pharmacol. Ther., 2005, 77(5), 415-426. (Pubitemid 40719269)
27. Iwata, H.; Tezuka, Y.; Kadota, S.; Hiratsuka, A.; Watabe, T. Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract. Drug Metab. Dispos., 2004, 32(12), 1351-1358. (Pubitemid 39564554)
28. Jiang, W.; Wang, X.; Xu, X.; Kong, L. Effect of Schisandra sphenanthera extract on the concentration of tacrolimus in the blood of liver transplant patients. Int. J. Clin. Pharmacol. Ther., 2010, 48(3), 224-229.
29. Xin, H.W.; Wu, X.C.; Li, Q.; Yu, A.R.; Zhu, M.; Shen, Y.; Su, D.; Xiong, L. Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers. Br. J. Clin. Pharmacol., 2007, 64(4), 469-475. (Pubitemid 47404309)
30. Nowack, R. Review article, cytochrome P450 enzyme, and transport protein mediated herb-drug interactions in renal transplant patients, grapefruit juice, St John's Wort - and beyond! Nephrology (Carlton), 2008, 13(4), 337-347. (Pubitemid 351668338)
31. Moore, L.B.; Goodwin, B.; Jones, S.A.; Wisely, G.B.; Serabjit- Singh, C.J.; Willson, T.M.; Collins, J.L.; Kliewer, S.A. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. U. S. A., 2000, 97(13), 7500-7502. (Pubitemid 30431492)
32. Wang, Z.; Gorski, J.C.; Hamman, M.A.; Huang, S.M.; Lesko, L.J.; Hall, S.D. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin. Pharmacol. Ther., 2001, 70(4), 317-326. (Pubitemid 33022472)
33. Obach, R.S. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J. Pharmacol. Exp. Ther., 2000, 294(1), 88-95. (Pubitemid 30434674)
34. Zou, L.; Harkey, M.R.; Henderson, G.L. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci., 2002, 71(13), 1579-1589. (Pubitemid 34808718)
35. Arold, G.; Donath, F.; Maurer, A.; Diefenbach, K.; Bauer, S.; Henneicke-Von Zepelin, H.H.; Friede, M.; Roots, I. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. Planta Med., 2005, 71(4), 331-337. (Pubitemid 40676457)
36. Bray, B.J.; Perry, N.B.; Menkes, D.B.; Rosengren, R.J. St. John's wort extract induces CYP3A and CYP2E1 in the Swiss Webster mouse. Toxicol. Sci., 2002, 66(1), 27-33. (Pubitemid 34202026)
37. Hellum, B.H.; Hu, Z.; Nilsen, O.G. Trade herbal products and induction of CYP2C19 and CYP2E1 in cultured human hepatocytes. Basic Clin Pharmacol Toxicol, 2009, 105(1), 58-63.
38. Strandell, J.; Neil, A.; Carlin, G. An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. Phytomedicine, 2004, 11(2-3), 98-104. (Pubitemid 38314048)
39. Mueller, S.C.; Majcher-Peszynska, J.; Uehleke, B.; Klammt, S.; Mundkowski, R.G.; Miekisch, W.; Sievers, H.; Bauer, S.; Frank, B.; Kundt, G.; Drewelow, B. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur. J. Clin. Pharmacol., 2006, 62(1), 29-36. (Pubitemid 43106313)
40. Chang, T.K.; Chen, J.; Teng, X.W. Distinct role of bilobalide and ginkgolide A in the modulation of rat CYP2B1 and CYP3A23 gene expression by Ginkgo biloba extract in cultured hepatocytes. Drug Metab. Dispos., 2006, 34(2), 234-242. (Pubitemid 43145025)
41. Chatterjee, S.S.; Doelman, C.J.; Noldner, M.; Biber, A.; Koch, E. Influence of the Ginkgo extract EGb 761 on rat liver cytochrome P450 and steroid metabolism and excretion in rats and man. J. Pharm. Pharmacol., 2005, 57(5), 641-650. (Pubitemid 40562403)
42. Deng, Y.; Bi, H.C.; Zhao, L.Z.; He, F.; Liu, Y.Q.; Yu, J.J.; Ou, Z.M.; Ding, L.; Chen, X.; Huang, Z.Y.; Huang, M.; Zhou, S.F. Induction of cytochrome P450s by terpene trilactones and flavonoids of the Ginkgo biloba extract EGb 761 in rats. Xenobiotica, 2008, 38(5), 465-481. (Pubitemid 351550976)
43. Deng, Y.; Bi, H.C.; Zhao, L.Z.; Wang, X.D.; Chen, J.; Ou, Z.M.; Ding, L.; Xu, L.J.; Guan, S.; Chen, X.; Zhou, S.F.; Huang, M. Induction of cytochrome P450 3A by the Ginkgo biloba extract and bilobalides in human and rat primary hepatocytes. Drug Metab. Lett., 2008, 2(1), 60-66. (Pubitemid 351411264)
44. Fan, L.; Tao, G.Y.; Wang, G.; Chen, Y.; Zhang, W.; He, Y.J.; Li, Q.; Lei, H.P.; Jiang, F.; Hu, D.L.; Huang, Y.F.; Zhou, H.H. Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers. Ann. Pharmacother., 2009, 43(5), 944-949.
45. Gaudineau, C.; Beckerman, R.; Welbourn, S.; Auclair, K. Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem. Biophys. Res. Commun., 2004, 318(4), 1072-1078. (Pubitemid 38625885)
46. Gurley, B.J.; Gardner, S.F.; Hubbard, M.A.; Williams, D.K.; Gentry, W.B.; Cui, Y.; Ang, C.Y. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin. Pharmacol. Ther., 2002, 72(3), 276-287.
47. Gurley, B.J.; Gardner, S.F.; Hubbard, M.A.; Williams, D.K.; Gentry, W.B.; Cui, Y.; Ang, C.Y. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly, St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging, 2005, 22(6), 525-539. (Pubitemid 41003065)
48. Mauro, V.F.; Mauro, L.S.; Kleshinski, J.F.; Khuder, S.A.; Wang, Y.; Erhardt, P.W. Impact of ginkgo biloba on the pharmacokinetics of digoxin. Am. J. Ther., 2003, 10(4), 247-251.
49. Mohutsky, M.A.; Anderson, G.D.; Miller, J.W.; Elmer, G.W. Ginkgo biloba, evaluation of CYP2C9 drug interactions in vitro and in vivo. Am. J. Ther., 2006, 13(1), 24-31. (Pubitemid 43162445)
50. Robertson, S.M.; Davey, R.T.; Voell, J.; Formentini, E.; Alfaro, R.M.; Penzak, S.R. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr. Med. Res. Opin., 2008, 24(2), 591-599. (Pubitemid 351294409)
51. Sugiyama, T.; Kubota, Y.; Shinozuka, K.; Yamada, S.; Yamada, K.; Umegaki, K. Induction and recovery of hepatic drug metabolizing enzymes in rats treated with Ginkgo biloba extract. Food Chem. Toxicol., 2004, 42(6), 953-957. (Pubitemid 38515779)
52. Yale, S.H.; Glurich, I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J. Altern. Complement. Med., 2005, 11(3), 433-439. (Pubitemid 40994577)
53. Yin, O.Q.; Tomlinson, B.; Waye, M.M.; Chow, A.H.; Chow, M.S. Pharmacogenetics and herb-drug interactions, experience with Ginkgo biloba and omeprazole. Pharmacogenetics, 2004, 14(12), 841-850. (Pubitemid 40054339)
54. Zuo, X.C.; Zhang, B.K.; Jia, S.J.; Liu, S.K.; Zhou, L.Y.; Li, J.; Zhang, J.; Dai, L.L.; Chen, B.M.; Yang, G.P.; Yuan, H. Effects of Ginkgo biloba extracts on diazepam metabolism, a pharmacokinetic study in healthy Chinese male subjects. Eur. J. Clin. Pharmacol., 2010, 66(5), 503-509.
55. Greenblatt, D.J.; Von Moltke, L.L.; Luo, Y.; Perloff, E.S.; Horan, K.A.; Bruce, A.; Reynolds, R.C.; Harmatz, J.S.; Avula, B.; Khan, I.A.; Goldman, P. Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J. Clin. Pharmacol., 2006, 46(2), 214-221. (Pubitemid 43149298)
56. He, N.; Edeki, T. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am. J. Ther., 2004, 11(3), 206-212.
57. He, N.; Xie, H.G.; Collins, X.; Edeki, T.; Yan, Z. Effects of individual ginsenosides, ginkgolides and flavonoids on CYP2C19 and CYP2D6 activity in human liver microsomes. Clin. Exp. Pharmacol. Physiol., 2006, 33(9), 813-815. (Pubitemid 44215135)
58. Hellum, B.H.; Hu, Z.; Nilsen, O.G. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin. Pharmacol. Toxicol., 2007, 100(1), 23-30. (Pubitemid 46051439)
59. Lau, A.J.; Chang, T.K. Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract, effect of terpene trilactones and flavonols. Drug Metab. Dispos., 2009, 37(9), 1931-1937.
60. Markowitz, J.S.; Donovan, J.L.; Lindsay Devane, C.; Sipkes, L.; Chavin, K.D. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J. Clin. Psychopharmacol., 2003, 23(6), 576-581. (Pubitemid 37443189)
61. Numa, A.M.; Abbott, F.S.; Chang, T.K. Effect of Ginkgo biloba extract on oxidative metabolism of valproic acid in hepatic microsomes from donors with the CYP2C9*1/*1 genotype. Can. J. Physiol. Pharmacol., 2007, 85(9), 848-855. (Pubitemid 350189726)
62. Ohnishi, N.; Kusuhara, M.; Yoshioka, M.; Kuroda, K.; Soga, A.; Nishikawa, F.; Koishi, T.; Nakagawa, M.; Hori, S.; Matsumoto, T.; Yamashita, M.; Ohta, S.; Takara, K.; Yokoyama, T. Studies on interactions between functional foods or dietary supplements and medicines. I. Effects of Ginkgo biloba leaf extract on the pharmacokinetics of diltiazem in rats. Biol. Pharm. Bull., 2003, 26(9), 1315-1320. (Pubitemid 41656569)
63. Rajaraman, G.; Chen, J.; Chang, T.K. Ginkgolide A contributes to the potentiation of acetaminophen toxicity by Ginkgo biloba extract in primary cultures of rat hepatocytes. Toxicol. Appl. Pharmacol., 2006, 217(2), 225-233. (Pubitemid 44708289)
64. Shinozuka, K.; Umegaki, K.; Kubota, Y.; Tanaka, N.; Mizuno, H.; Yamauchi, J.; Nakamura, K.; Kunitomo, M. Feeding of Ginkgo biloba extract (GBE) enhances gene expression of hepatic cytochrome P-450 and attenuates the hypotensive effect of nicardipine in rats. Life Sci., 2002, 70(23), 2783-2792. (Pubitemid 34312011)
65. Sugiyama, T.; Kubota, Y.; Shinozuka, K.; Yamada, S.; Wu, J.; Umegaki, K. Ginkgo biloba extract modifies hypoglycemic action of tolbutamide via hepatic cytochrome P450 mediated mechanism in aged rats. Life Sci., 2004, 75(9), 1113-1122. (Pubitemid 38780993)
66. Uchida, S.; Yamada, H.; Li, X.D.; Maruyama, S.; Ohmori, Y.; Oki, T.; Watanabe, H.; Umegaki, K.; Ohashi, K.; Yamada, S. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J. Clin. Pharmacol., 2006, 46(11), 1290-1298. (Pubitemid 44564357)
67. Umegaki, K.; Saito, K.; Kubota, Y.; Sanada, H.; Yamada, K.; Shinozuka, K. Ginkgo biloba extract markedly induces pentoxyresorufin O-dealkylase activity in rats. Jpn. J. Pharmacol., 2002, 90(4), 345-351. (Pubitemid 36096890)
68. Von Moltke, L.L.; Weemhoff, J.L.; Bedir, E.; Khan, I.A.; Harmatz, J.S.; Goldman, P.; Greenblatt, D.J. Inhibition of human cytochromes P450 by components of Ginkgo biloba. J. Pharm. Pharmacol., 2004, 56(8), 1039-1044. (Pubitemid 39140060)
69. Yang, X.F.; Wang, N.P.; Lu, W.H.; Zeng, F.D. Effects of Ginkgo biloba extract and tanshinone on cytochrome P-450 isozymes and glutathione transferase in rats. Acta Pharmacol. Sin., 2003, 24(10), 1033-1038.
70. Yeung, E.Y.; Sueyoshi, T.; Negishi, M.; Chang, T.K. Identification of Ginkgo biloba as a novel activator of pregnane X receptor. Drug Metab. Dispos., 2008, 36(11), 2270-2276.
71. Yoshioka, M.; Ohnishi, N.; Koishi, T.; Obata, Y.; Nakagawa, M.; Matsumoto, T.; Tagagi, K.; Takara, K.; Ohkuni, T.; Yokoyama, T.; Kuroda, K. Studies on interactions between functional foods or dietary supplements and medicines. IV. Effects of ginkgo biloba leaf extract on the pharmacokinetics and pharmacodynamics of nifedipine in healthy volunteers. Biol. Pharm. Bull., 2004, 27(12), 2006-2009. (Pubitemid 41701579)
72. Zhao, L.Z.; Huang, M.; Chen, J.; Ee, P.L.; Chan, E.; Duan, W.; Guan, Y.Y.; Hong, Y.H.; Chen, X.; Zhou, S. Induction of propranolol metabolism by Ginkgo biloba extract EGb 761 in rats. Curr. Drug Metab., 2006, 7(6), 577-587. (Pubitemid 44226586)
73. Berginc, K.; Trdan, T.; Trontelj, J.; Kristl, A. HIV protease inhibitors, garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy. Biopharm. Drug Dispos., 2010, 31(8-9), 495-505.
74. Cox, M.C.; Low, J.; Lee, J.; Walshe, J.; Denduluri, N.; Berman, A.; Permenter, M.G.; Petros, W.P.; Price, D.K.; Figg, W.D.; Sparreboom, A.; Swain, S.M. Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin. Cancer Res., 2006, 12(15), 4636-4640. (Pubitemid 44297815)
75. Dalvi, R.R. Alterations in hepatic phase I and phase II biotransformation enzymes by garlic oil in rats. Toxicol. Lett., 1992, 60(3), 299-305.
76. Foster, B.C.; Foster, M.S.; Vandenhoek, S.; Krantis, A.; Budzinski, J.W.; Arnason, J.T.; Gallicano, K.D.; Choudri, S. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm. Pharm. Sci., 2001, 4(2), 176-184. (Pubitemid 34305609)
77. Gallicano, K.; Foster, B.; Choudhri, S. Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br. J. Clin. Pharmacol., 2003, 55(2), 199-202. (Pubitemid 36237866)
78. Greenblatt, D.J.; Leigh-Pemberton, R.A.; Von Moltke, L.L. In vitro interactions of water-soluble garlic components with human cytochromes p450. J. Nutr., 2006, 136(3 Suppl), 806S-809S. (Pubitemid 43363781)
79. Haber, D.; Siess, M.H.; De Waziers, I.; Beaune, P.; Suschetet, M. Modification of hepatic drug-metabolizing enzymes in rat fed naturally occurring allyl sulphides. Xenobiotica, 1994, 24(2), 169-182. (Pubitemid 24104503)
80. Ho, B.E.; Shen, D.D.; Mccune, J.S.; Bui, T.; Risler, L.; Yang, Z.; Ho, R.J. Effects of Garlic on Cytochromes P450 2C9- and 3A4- Mediated Drug Metabolism in Human Hepatocytes. Sci. Pharm., 2010, 78(3), 473-481.
81. Le Bon, A.M.; Vernevaut, M.F.; Guenot, L.; Kahane, R.; Auger, J.; Arnault, I.; Haffner, T.; Siess, M.H. Effects of garlic powders with varying alliin contents on hepatic drug metabolizing enzymes in rats. J. Agric. Food Chem., 2003, 51(26), 7617-7623.
82. Markowitz, J.S.; Devane, C.L.; Chavin, K.D.; Taylor, R.M.; Ruan, Y.; Donovan, J.L. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin. Pharmacol. Ther., 2003, 74(2), 170-177. (Pubitemid 36951814)
83. Wu, C.C.; Sheen, L.Y.; Chen, H.W.; Kuo, W.W.; Tsai, S.J.; Lii, C.K. Differential effects of garlic oil and its three major organosulfur components on the hepatic detoxification system in rats. J. Agric. Food Chem., 2002, 50(2), 378-383.
84. Foti, R.S.; Wahlstrom, J.L.; Wienkers, L.C. The in vitro drug interaction potential of dietary supplements containing multiple herbal components. Drug Metab. Dispos., 2007, 35(2), 185-188. (Pubitemid 46148728)
85. Gorski, J.C.; Huang, S.M.; Pinto, A.; Hamman, M.A.; Hilligoss, J.K.; Zaheer, N.A.; Desai, M.; Miller, M.; Hall, S.D. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin. Pharmacol. Ther., 2004, 75(1), 89-100. (Pubitemid 38130121)
86. Gurley, B.J.; Gardner, S.F.; Hubbard, M.A.; Williams, D.K.; Gentry, W.B.; Carrier, J.; Khan, I.A.; Edwards, D.J.; Shah, A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes, Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin. Pharmacol. Ther., 2004, 76(5), 428-440. (Pubitemid 39469867)
87. Gurley, B.J.; Swain, A.; Hubbard, M.A.; Williams, D.K.; Barone, G.; Hartsfield, F.; Tong, Y.; Carrier, D.J.; Cheboyina, S.; Battu, S.K. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans, effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol. Nutr. Food Res., 2008, 52(7), 755-763.
88. Hansen, T.S.; Nilsen, O.G. In vitro CYP3A4 metabolism, inhibition by Echinacea purpurea and choice of substrate for the evaluation of herbal inhibition. Basic Clin. Pharmacol. Toxicol., 2008, 103(5), 445-449.
89. Modarai, M.; Gertsch, J.; Suter, A.; Heinrich, M.; Kortenkamp, A. Cytochrome P450 inhibitory action of Echinacea preparations differs widely and co-varies with alkylamide content. J. Pharm. Pharmacol., 2007, 59(4), 567-573. (Pubitemid 47051131)
90. Modarai, M.; Yang, M.; Suter, A.; Kortenkamp, A.; Heinrich, M. Metabolomic profiling of liquid Echinacea medicinal products with in vitro inhibitory effects on cytochrome P450 3A4 (CYP3A4). Planta Med., 2010, 76(4), 378-385.
91. Mrozikiewicz, P.M.; Bogacz, A.; Karasiewicz, M.; Mikolajczak, P.L.; Ozarowski, M.; Seremak-Mrozikiewicz, A.; Czerny, B.; Bobkiewicz-Kozlowska, T.; Grzeskowiak, E. The effect of standardized Echinacea purpurea extract on rat cytochrome P450 expression level. Phytomedicine, 2010, 17(10), 830-833.
92. Bell, E.C.; Ravis, W.R.; Chan, H.M.; Lin, Y.J. Lack of pharmacokinetic interaction between St. John's wort and prednisone. Ann. Pharmacother., 2007, 41(11), 1819-1824. (Pubitemid 350044344)
93. Budzinski, J.W.; Foster, B.C.; Vandenhoek, S.; Arnason, J.T. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine, 2000, 7(4), 273-282. (Pubitemid 30618491)
94. Burstein, A.H.; Horton, R.L.; Dunn, T.; Alfaro, R.M.; Piscitelli, S.C.; Theodore, W. Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. Clin. Pharmacol. Ther., 2000, 68(6), 605-612. (Pubitemid 32059986)
95. Dresser, G.K.; Schwarz, U.I.; Wilkinson, G.R.; Kim, R.B. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin. Pharmacol. Ther., 2003, 73(1), 41-50. (Pubitemid 36158485)
96. Durr, D.; Stieger, B.; Kullak-Ublick, G.A.; Rentsch, K.M.; Steinert, H.C.; Meier, P.J.; Fattinger, K. St John's Wort induces intestinal Pglycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther., 2000, 68(6), 598-604. (Pubitemid 32059985)
97. Frye, R.F.; Fitzgerald, S.M.; Lagattuta, T.F.; Hruska, M.W.; Egorin, M.J. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin. Pharmacol. Ther., 2004, 76(4), 323-329. (Pubitemid 39313122)
98. Goodwin, B.; Moore, L.B.; Stoltz, C.M.; Mckee, D.D.; Kliewer, S.A. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol. Pharmacol., 2001, 60(3), 427-431. (Pubitemid 32781548)
99. Hall, S.D.; Wang, Z.; Huang, S.M.; Hamman, M.A.; Vasavada, N.; Adigun, A.Q.; Hilligoss, J.K.; Miller, M.; Gorski, J.C. The interaction between St John's wort and an oral contraceptive. Clin. Pharmacol. Ther., 2003, 74(6), 525-535. (Pubitemid 37521996)
100. Henderson, L.; Yue, Q.Y.; Bergquist, C.; Gerden, B.; Arlett, P. St John's wort (Hypericum perforatum), drug interactions and clinical outcomes. Br. J. Clin. Pharmacol., 2002, 54(4), 349-356. (Pubitemid 35334946)
101. Jiang, X.; Williams, K.M.; Liauw, W.S.; Ammit, A.J.; Roufogalis, B.D.; Duke, C.C.; Day, R.O.; Mclachlan, A.J. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br. J. Clin. Pharmacol., 2004, 57(5), 592-599. (Pubitemid 38582179)
102. Kawaguchi, A.; Ohmori, M.; Tsuruoka, S.; Nishiki, K.; Harada, K.; Miyamori, I.; Yano, R.; Nakamura, T.; Masada, M.; Fujimura, A. Drug interaction between St John's Wort and quazepam. Br. J. Clin. Pharmacol., 2004, 58(4), 403-410. (Pubitemid 39312464)
103. Mai, I.; Bauer, S.; Perloff, E.S.; Johne, A.; Uehleke, B.; Frank, B.; Budde, K.; Roots, I. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin. Pharmacol. Ther., 2004, 76(4), 330-340. (Pubitemid 39313123)
104. Markowitz, J.S.; Devane, C.L.; Boulton, D.W.; Carson, S.W.; Nahas, Z.; Risch, S.C. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci., 2000, 66(9), PL133-139.
105. Markowitz, J.S.; Donovan, J.L.; Devane, C.L.; Taylor, R.M.; Ruan, Y.; Wang, J.S.; Chavin, K.D. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA, 2003, 290(11), 1500-1504. (Pubitemid 37430406)
106. Morimoto, T.; Kotegawa, T.; Tsutsumi, K.; Ohtani, Y.; Imai, H.; Nakano, S. Effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers. J. Clin. Pharmacol., 2004, 44(1), 95-101. (Pubitemid 38005099)
107. Mueller, S.C.; Uehleke, B.; Woehling, H.; Petzsch, M.; Majcher-Peszynska, J.; Hehl, E.M.; Sievers, H.; Frank, B.; Riethling, A.K.; Drewelow, B. Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin. Clin. Pharmacol. Ther., 2004, 75(6), 546-557. (Pubitemid 38746605)
108. Portoles, A.; Terleira, A.; Calvo, A.; Martinez, I.; Resplandy, G. Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers, an open-label, pharmacokinetic interaction clinical trial. J. Clin. Pharmacol., 2006, 46(10), 1188-1194. (Pubitemid 44387419)
109. Rengelshausen, J.; Banfield, M.; Riedel, K.D.; Burhenne, J.; Weiss, J.; Thomsen, T.; Walter-Sack, I.; Haefeli, W.E.; Mikus, G. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin. Pharmacol. Ther., 2005, 78(1), 25-33. (Pubitemid 40956928)
110. Roby, C.A.; Anderson, G.D.; Kantor, E.; Dryer, D.A.; Burstein, A.H. St John's Wort, effect on CYP3A4 activity. Clin. Pharmacol. Ther., 2000, 67(5), 451-457. (Pubitemid 30327483)
111. Roby, C.A.; Dryer, D.A.; Burstein, A.H. St. John's wort, effect on CYP2D6 activity using dextromethorphan-dextrorphan ratios. J. Clin. Psychopharmacol., 2001, 21(5), 530-532. (Pubitemid 32937438)
112. Smith, P.F.; Bullock, J.M.; Booker, B.M.; Haas, C.E.; Berenson, C.S.; Jusko, W.J. Induction of imatinib metabolism by hypericum perforatum. Blood, 2004, 104(4), 1229-1230. (Pubitemid 39038051)
113. Sugimoto, K.; Ohmori, M.; Tsuruoka, S.; Nishiki, K.; Kawaguchi, A.; Harada, K.; Arakawa, M.; Sakamoto, K.; Masada, M.; Miyamori, I.; Fujimura, A. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin. Pharmacol. Ther., 2001, 70(6), 518-524. (Pubitemid 34008408)
114. Tannergren, C.; Engman, H.; Knutson, L.; Hedeland, M.; Bondesson, U.; Lennernas, H. St John's wort decreases the bioavailability of R- and S-verapamil through induction of the firstpass metabolism. Clin. Pharmacol. Ther., 2004, 75(4), 298-309. (Pubitemid 38471555)
115. Wang, X.D.; Li, J.L.; Su, Q.B.; Guan, S.; Chen, J.; Du, J.; He, Y.W.; Zeng, J.; Zhang, J.X.; Chen, X.; Huang, M.; Zhou, S.F. Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John's wort-induced activity of cytochrome P450 3A4 enzyme. Br. J. Clin. Pharmacol., 2009, 67(2), 255-261.
116. Wang, Z.; Hamman, M.A.; Huang, S.M.; Lesko, L.J.; Hall, S.D. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin. Pharmacol. Ther., 2002, 71(6), 414-420. (Pubitemid 34701348)
117. Wenk, M.; Todesco, L.; Krahenbuhl, S. Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br. J. Clin. Pharmacol., 2004, 57(4), 495-499. (Pubitemid 38519655)
118. Wentworth, J.M.; Agostini, M.; Love, J.; Schwabe, J.W.; Chatterjee, V.K. St John's wort, a herbal antidepressant, activates the steroid X receptor. J. Endocrinol., 2000, 166(3), R11-16.
119. Xie, R.; Tan, L.H.; Polasek, E.C.; Hong, C.; Teillol-Foo, M.; Gordi, T.; Sharma, A.; Nickens, D.J.; Arakawa, T.; Knuth, D.W.; Antal, E.J. CYP3A and P-glycoprotein activity induction with St. John's Wort in healthy volunteers from 6 ethnic populations. J. Clin. Pharmacol., 2005, 45(3), 352-356. (Pubitemid 40490432)
120. Anderson, G.D.; Rosito, G.; Mohustsy, M.A.; Elmer, G.W. Drug interaction potential of soy extract and Panax ginseng. J. Clin. Pharmacol., 2003, 43(6), 643-648. (Pubitemid 36613123)
121. Donovan, J.L.; Devane, C.L.; Chavin, K.D.; Taylor, R.M.; Markowitz, J.S. Siberian ginseng (Eleutheroccus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab. Dispos., 2003, 31(5), 519-522. (Pubitemid 36444158)
122. Henderson, G.L.; Harkey, M.R.; Gershwin, M.E.; Hackman, R.M.; Stern, J.S.; Stresser, D.M. Effects of ginseng components on c- DNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci., 1999, 65(15), PL209-214.
123. Yu, C.T.; Chen, J.; Teng, X.W.; Tong, V.; Chang, T.K. Lack of evidence for induction of CYP2B1, CYP3A23, and CYP1A2 gene expression by Panax ginseng and Panax quinquefolius extracts in adult rats and primary cultures of rat hepatocytes. Drug Metab. Dispos., 2005, 33(1), 19-22. (Pubitemid 40023509)
124. Beckmann-Knopp, S.; Rietbrock, S.; Weyhenmeyer, R.; Bocker, R.H.; Beckurts, K.T.; Lang, W.; Hunz, M.; Fuhr, U. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol. Toxicol., 2000, 86(6), 250-256. (Pubitemid 30413400)
125. Brantley, S.J.; Oberlies, N.H.; Kroll, D.J.; Paine, M.F. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. J. Pharmacol. Exp. Ther., 2010, 332(3), 1081-1087.
126. Chang, J.C.; Wu, Y.T.; Lee, W.C.; Lin, L.C.; Tsai, T.H. Herb-drug interaction of silymarin or silibinin on the pharmacokinetics of trazodone in rats. Chem. Biol. Interact., 2009, 182(2-3), 227-232.
127. Doehmer, J.; Weiss, G.; Mcgregor, G.P.; Appel, K. Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities. Toxicol In Vitro, 2011, 25(1), 21-27.
128. Fuhr, U.; Beckmann-Knopp, S.; Jetter, A.; Luck, H.; Mengs, U. The effect of silymarin on oral nifedipine pharmacokinetics. Planta Med., 2007, 73(14), 1429-1435. (Pubitemid 350240497)
129. Gurley, B.; Hubbard, M.A.; Williams, D.K.; Thaden, J.; Tong, Y.; Gentry, W.B.; Breen, P.; Carrier, D.J.; Cheboyina, S. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity, comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J. Clin. Pharmacol., 2006, 46(2), 201-213. (Pubitemid 43149297)
130. Mills, E.; Wilson, K.; Clarke, M.; Foster, B.; Walker, S.; Rachlis, B.; Degroot, N.; Montori, V.M.; Gold, W.; Phillips, E.; Myers, S.; Gallicano, K. Milk thistle and indinavir, a randomized controlled pharmacokinetics study and meta-analysis. Eur. J. Clin. Pharmacol., 2005, 61(1), 1-7. (Pubitemid 40558272)
131. Piscitelli, S.C.; Formentini, E.; Burstein, A.H.; Alfaro, R.; Jagannatha, S.; Falloon, J. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy, 2002, 22(5), 551-556. (Pubitemid 34464940)
132. Sridar, C.; Goosen, T.C.; Kent, U.M.; Williams, J.A.; Hollenberg, P.F. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab. Dispos., 2004, 32(6), 587-594. (Pubitemid 38668150)
133. Van Erp, N.P.; Baker, S.D.; Zhao, M.; Rudek, M.A.; Guchelaar, H.J.; Nortier, J.W.; Sparreboom, A.; Gelderblom, H. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin. Cancer Res., 2005, 11(21), 7800-7806. (Pubitemid 41611624)
134. Venkataramanan, R.; Ramachandran, V.; Komoroski, B.J.; Zhang, S.; Schiff, P.L.; Strom, S.C. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab. Dispos., 2000, 28(11), 1270-1273.
135. Gurley, B.J.; Swain, A.; Hubbard, M.A.; Hartsfield, F.; Thaden, J.; Williams, D.K.; Gentry, W.B.; Tong, Y. Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin. Pharmacol. Ther., 2008, 83(1), 61-69.
136. Lim, S.T.; Dragull, K.; Tang, C.S.; Bittenbender, H.C.; Efird, J.T.; Nerurkar, P.V. Effects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats. Toxicol. Sci., 2007, 97(1), 214-221. (Pubitemid 47072170)
137. Mathews, J.M.; Etheridge, A.S.; Black, S.R. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab. Dispos., 2002, 30(11), 1153-1157. (Pubitemid 35265819)
138. Raucy, J.L. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab. Dispos., 2003, 31(5), 533-539. (Pubitemid 36444161)
139. Ueng, Y.F.; Kuo, Y.H.; Wang, S.Y.; Lin, Y.L.; Chen, C.F. Induction of CYP1A by a diterpene quinone tanshinone IIA isolated from a medicinal herb Salvia miltiorrhiza in C57BL/6J but not in DBA/2J mice. Life Sci., 2004, 74(7), 885-896.
140. Unger, M.; Holzgrabe, U.; Jacobsen, W.; Cummins, C.; Benet, L.Z. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). Planta Med., 2002, 68(12), 1055-1058. (Pubitemid 36140306)
141. Yamazaki, Y.; Hashida, H.; Arita, A.; Hamaguchi, K.; Shimura, F. High dose of commercial products of kava (Piper methysticum) markedly enhanced hepatic cytochrome P450 1A1 mRNA expression with liver enlargement in rats. Food Chem. Toxicol., 2008, 46(12), 3732-3738.
142. Yueh, M.F.; Kawahara, M.; Raucy, J. High volume bioassays to assess CYP3A4-mediated drug interactions, induction and inhibition in a single cell line. Drug Metab. Dispos., 2005, 33(1), 38-48. (Pubitemid 40023512)
143. Pang, X.; Cheng, J.; Krausz, K.W.; Guo, D.A.; Gonzalez, F.J. Pregnane X receptor-mediated induction of Cyp3a by black cohosh. Xenobiotica, 2010.
144. Kuo, Y.H.; Lin, Y.L.; Don, M.J.; Chen, R.M.; Ueng, Y.F. Induction of cytochrome P450-dependent monooxygenase by extracts of the medicinal herb Salvia miltiorrhiza. J. Pharm. Pharmacol., 2006, 58(4), 521-527.
145. Qiu, F.; Wang, G.; Zhang, R.; Sun, J.; Jiang, J.; Ma, Y. Effect of danshen extract on the activity of CYP3A4 in healthy volunteers. Br. J. Clin. Pharmacol., 2010, 69(6), 656-662.
146. Wang, X.; Cheung, C.M.; Lee, W.Y.; Or, P.M.; Yeung, J.H. Major tanshinones of Danshen (Salvia miltiorrhiza) exhibit different modes of inhibition on human CYP1A2, CYP2C9, CYP2E1 and CYP3A4 activities in vitro. Phytomedicine, 2010, 17(11), 868-875.
147. Wu, W.W.; Yeung, J.H. Inhibition of warfarin hydroxylation by major tanshinones of Danshen (Salvia miltiorrhiza) in the rat in vitro and in vivo. Phytomedicine, 2010, 17(3-4), 219-226.
148. Yu, C.; Ye, S.; Sun, H.; Liu, Y.; Gao, L.; Shen, C.; Chen, S.; Zeng, S. PXR-mediated transcriptional activation of CYP3A4 by cryptotanshinone and tanshinone IIA. Chem. Biol. Interact., 2009, 177(1), 58-64.
149. Donovan, J.L.; Chavin, K.D.; Devane, C.L.; Taylor, R.M.; Wang, J.S.; Ruan, Y.; Markowitz, J.S. Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. Drug Metab. Dispos., 2004, 32(9), 906-908. (Pubitemid 39096049)
150. Mirkov, S.; Komoroski, B.J.; Ramirez, J.; Graber, A.Y.; Ratain, M.J.; Strom, S.C.; Innocenti, F. Effects of green tea compounds on irinotecan metabolism. Drug Metab. Dispos., 2007, 35(2), 228-233. (Pubitemid 46148734)
151. Nishikawa, M.; Ariyoshi, N.; Kotani, A.; Ishii, I.; Nakamura, H.; Nakasa, H.; Ida, M.; Kimura, N.; Kimura, M.; Hasegawa, A.; Kusu, F.; Ohmori, S.; Nakazawa, K.; Kitada, M. Effects of continuous ingestion of green tea or grape seed extracts on the pharmacokinetics of midazolam. Drug Metab. Pharmacokinet., 2004, 19(4), 280-289.
152. Lan, K.; Jia, W. An integrated metabolomics and pharmacokinetics strategy for multi-component drugs evaluation. Curr. Drug Metab., 2010, 11(1), 105-114.
153. Bent, S.; Ko, R. Commonly used herbal medicines in the United States, a review. Am. J. Med., 2004, 116(7), 478-485. (Pubitemid 38388618)
154. Harkey, M.R.; Henderson, G.L.; Gershwin, M.E.; Stern, J.S.; Hackman, R.M. Variability in commercial ginseng products, an analysis of 25 preparations. Am. J. Clin. Nutr., 2001, 73(6), 1101-1106. (Pubitemid 32496951)
155. Chang, T.K.; Chen, J.; Benetton, S.A. In vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1. Drug Metab. Dispos., 2002, 30(4), 378-384. (Pubitemid 34263821)
156. Fahmi, O.A.; Maurer, T.S.; Kish, M.; Cardenas, E.; Boldt, S.; Nettleton, D. A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab. Dispos., 2008, 36(8), 1698-1708.
157. Van Beek, T.A.; Montoro, P. Chemical analysis and quality control of Ginkgo biloba leaves, extracts, and phytopharmaceuticals. J. Chromatogr. A, 2009, 1216(11), 2002-2032.
158. Hao, H.; Cui, N.; Wang, G.; Xiang, B.; Liang, Y.; Xu, X.; Zhang, H.; Yang, J.; Zheng, C.; Wu, L.; Gong, P.; Wang, W. Global detection and identification of nontarget components from herbal preparations by liquid chromatography hybrid ion trap time-offlight mass spectrometry and a strategy. Anal. Chem., 2008, 80(21), 8187-8194.
159. Liang, Y.; Hao, H.; Kang, A.; Xie, L.; Xie, T.; Zheng, X.; Dai, C.; Wan, L.; Sheng, L.; Wang, G. Qualitative and quantitative determination of complicated herbal components by liquid chromatography hybrid ion trap time-of-flight mass spectrometry and a relative exposure approach to herbal pharmacokinetics independent of standards. J. Chromatogr. A., 2010, 1217(30), 4971-4979.
160. Zheng, C.; Hao, H.; Wang, X.; Wu, X.; Wang, G.; Sang, G.; Liang, Y.; Xie, L.; Xia, C.; Yao, X. Diagnostic fragment-ion-based extension strategy for rapid screening and identification of serial components of homologous families contained in traditional Chinese medicine prescription using high-resolution LC-ESI- ITTOF/MS, Shengmai injection as an example. J. Mass Spectrom., 2009, 44(2), 230-244.
161. Zhou, J.L.; Qi, L.W.; Li, P. Herbal medicine analysis by liquid chromatography/time-of-flight mass spectrometry. J. Chromatogr. A., 2009, 1216(44), 7582-7594.
162. Sonoda, J.; Rosenfeld, J.M.; Xu, L.; Evans, R.M.; Xie, W. A nuclear receptor-mediated xenobiotic response and its implication in drug metabolism and host protection. Curr. Drug Metab., 2003, 4(1), 59-72. (Pubitemid 36131684)
163. Kocarek, T.A.; Schuetz, E.G.; Guzelian, P.S. Biphasic regulation of cytochrome P450 2B1/2 mRNA expression by dexamethasone in primary cultures of adult rat hepatocytes maintained on matrigel. Biochem. Pharmacol., 1994, 48(9), 1815-1822. (Pubitemid 24339008)
164. Kang, I.H.; Kim, H.J.; Oh, H.; Park, Y.I.; Dong, M.S. Biphasic effects of the flavonoids quercetin and naringenin on the metabolic activation of 2-amino-3,5-dimethylimidazo[4,5-f]quinoline by Salmonella typhimurium TA1538 co-expressing human cytochrome P450 1A2, NADPH-cytochrome P450 reductase, and cytochrome b5. Mutat. Res., 2004, 545(1-2), 37-47. (Pubitemid 38036989)
165. Lai, L.; Hao, H.; Wang, Q.; Zheng, C.; Zhou, F.; Liu, Y.; Wang, Y.; Yu, G.; Kang, A.; Peng, Y.; Wang, G.; Chen, X. Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats. Drug Metab. Dispos., 2009, 37(12), 2399-2407.
166. Atkins, W.M. Current views on the fundamental mechanisms of cytochrome P450 allosterism. Expert Opin. Drug Metab. Toxicol., 2006, 2(4), 573-579. (Pubitemid 46118327)
167. Xie, H.G.; Kim, R.B. St John's wort-associated drug interactions, short-term inhibition and long-term induction? Clin. Pharmacol. Ther., 2005, 78(1), 19-24. (Pubitemid 40956927)
168. Schmiedlin-Ren, P.; Edwards, D.J.; Fitzsimmons, M.E.; He, K.; Lown, K.S.; Woster, P.M.; Rahman, A.; Thummel, K.E.; Fisher, J.M.; Hollenberg, P.F.; Watkins, P.B. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanismbased inactivation by furanocoumarins. Drug Metab. Dispos., 1997, 25(11), 1228-1233. (Pubitemid 27490665)
169. Hu, N.; Xie, S.; Liu, L.; Wang, X.; Pan, X.; Chen, G.; Zhang, L.; Liu, H.; Liu, X.; Xie, L.; Wang, G. Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats. Drug Metab. Dispos., 2011, 39(3), 419-425.
170. Haber, D.; Siess, M.H.; Canivenc-Lavier, M.C.; Le Bon, A.M.; Suschetet, M. Differential effects of dietary diallyl sulfide and diallyl disulfide on rat intestinal and hepatic drug-metabolizing enzymes. J. Toxicol. Environ. Health, 1995, 44(4), 423-434.
171. Mcginnity, D.F.; Waters, N.J.; Tucker, J.; Riley, R.J. Integrated in vitro analysis for the in vivo prediction of cytochrome P450- mediated drug-drug interactions. Drug Metab. Dispos., 2008, 36(6), 1126-1134. (Pubitemid 351717471)
172. Markowitz, J.S.; Donovan, J.L.; Devane, C.L.; Taylor, R.M.; Ruan, Y.; Wang, J.S.; Chavin, K.D. Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. Clin. Pharmacol. Ther., 2003, 74(6), 536-542. (Pubitemid 37521997)
173. Liu, Y.; Zhang, J.W.; Li, W.; Ma, H.; Sun, J.; Deng, M.C.; Yang, L. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol. Sci., 2006, 91(2), 356-364. (Pubitemid 43827288)
174. Hao, M.; Ba, Q.; Yin, J.; Li, J.; Zhao, Y.; Wang, H. Deglycosylated ginsenosides are more potent inducers of CYP1A1, CYP1A2 and CYP3A4 expression in HepG2 cells than glycosylated ginsenosides. Drug Metab. Pharmacokinet., 2010.
175. Qiu, F.; Zhang, R.; Sun, J.; Jiye, A.; Hao, H.; Peng, Y.; Ai, H.; Wang, G. Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metab. Dispos., 2008, 36(7), 1308-1314. (Pubitemid 351929315)
176. Qiu, F.; Wang, G.; Zhao, Y.; Sun, H.; Mao, G.; A, J.; Sun, J. Effect of danshen extract on pharmacokinetics of theophylline in healthy volunteers. Br. J. Clin. Pharmacol., 2008, 65(2), 270-274. (Pubitemid 351192820)
177. Hao, H.; Wang, G.; Cui, N.; Li, J.; Xie, L.; Ding, Z. Pharmacokinetics, absorption and tissue distribution of tanshinone IIA solid dispersion. Planta Med., 2006, 72(14), 1311-1317. (Pubitemid 44862033)
178. Hao, H.; Wang, G.; Cui, N.; Li, J.; Xie, L.; Ding, Z. Identification of a novel intestinal first pass metabolic pathway, NQO1 mediated quinone reduction and subsequent glucuronidation. Curr. Drug Metab., 2007, 8(2), 137-149. (Pubitemid 46218680)
179. Yang, J.; Liao, M.; Shou, M.; Jamei, M.; Yeo, K.R.; Tucker, G.T.; Rostami-Hodjegan, A. Cytochrome p450 turnover, regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr. Drug Metab., 2008, 9(5), 384-394.
180. Brown, H.S.; Galetin, A.; Hallifax, D.; Houston, J.B. Prediction of in vivo drug-drug interactions from in vitro data , factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin. Pharmacokinet., 2006, 45(10), 1035-1050. (Pubitemid 44436005)
181. Obach, R.S. Predicting drug-drug interactions from in vitro drug metabolism data, challenges and recent advances. Curr. Opin. Drug Discov. Devel., 2009, 12(1), 81-89.
182. 182] Singh, S.S. Preclinical pharmacokinetics, an approach towards safer and efficacious drugs. Curr. Drug Metab., 2006, 7(2), 165-182.
183. Lin, J.H. Applications and limitations of genetically modified mouse models in drug discovery and development. Curr. Drug Metab., 2008, 9(5), 419-438. (Pubitemid 352025196)
184. Shord, S.S.; Shah, K.; Lukose, A. Drug-botanical interactions, a review of the laboratory, animal, and human data for 8 common botanicals. Integr. Cancer Ther., 2009, 8(3), 208-227.
185. Muruganandan, S.; Sinal, C.J. Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism. Clin. Pharmacol. Ther., 2008, 83(6), 818-828. (Pubitemid 351704925)
186. Marathe, P.H.; Rodrigues, A.D. In vivo animal models for investigating potential CYP3A- and Pgp-mediated drug-drug interactions. Curr. Drug Metab., 2006, 7(7), 687-704. (Pubitemid 44509676)
187. Kishimoto, R.; Ueda, M.; Yoshinaga, H.; Goda, K.; Park, S.S. Combined effects of ethanol and garlic on hepatic ethanol metabolism in mice. J. Nutr. Sci. Vitaminol. (Tokyo). 1999, 45(3), 275-286. (Pubitemid 29330338)
188. Loizou, G.D.; Cocker, J. The effects of alcohol and diallyl sulphide on CYP2E1 activity in humans, a phenotyping study using chlorzoxazone. Hum. Exp. Toxicol., 2001, 20(7), 321-327. (Pubitemid 32798729)
189. Cao, Y.F.; Zhang, Y.Y.; Li, J.; Ge, G.B.; Hu, D.; Liu, H.X.; Huang, T.; Wang, Y.C.; Fang, Z.Z.; Sun, D.X.; Huo, H.; Yin, J.; Yang, L. CYP3A catalyses schizandrin biotransformation in human, minipig and rat liver microsomes. Xenobiotica, 2010, 40(1), 38-47.
190. Moriguchi, T.; Motohashi, H.; Hosoya, T.; Nakajima, O.; Takahashi, S.; Ohsako, S.; Aoki, Y.; Nishimura, N.; Tohyama, C.; Fujii-Kuriyama, Y.; Yamamoto, M. Distinct response to dioxin in an arylhydrocarbon receptor (AHR)-humanized mouse. Proc. Natl. Acad. Sci. U. S. A., 2003, 100(10), 5652-5657. (Pubitemid 36576863)
191. Zordoky, B.N.; El-Kadi, A.O. Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure. Curr. Drug Metab., 2008, 9(2), 122-128. (Pubitemid 351461001)
192. Renton, K.W. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin. Drug Metab. Toxicol., 2005, 1(4), 629-640.
193. Nolin, T.D.; Frye, R.F.; Matzke, G.R. Hepatic drug metabolism and transport in patients with kidney disease. Am. J. Kidney Dis., 2003, 42(5), 906-925. (Pubitemid 37322908)
194. Renton, K.W. Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr. Drug Metab., 2004, 5(3), 235-243. (Pubitemid 38735778)
195. Xie, Y.; Hao, H.P.; Kang, A.; Liang, Y.; Xie, T.; Sun, S.Q.; Dai, C.; Zheng, X.A.; Xie, L.; Li, J.A.; Wang, G.J. Integral pharmacokinetics of multiple lignan components in normal, CCl4- induced hepatic injury and hepatoprotective agents pretreated rats and correlations with hepatic injury biomarkers. J. Ethnopharmacol., 2010, 131(2), 290-299.
196. Zordoky, B.N.; El-Kadi, A.O. Role of NF-kappaB in the regulation of cytochrome P450 enzymes. Curr. Drug Metab., 2009, 10(2), 164-178.
197. Bastien, M.C.; Leblond, F.; Pichette, V.; Villeneuve, J.P. Differential alteration of cytochrome P450 isoenzymes in two experimental models of cirrhosis. Can. J. Physiol. Pharmacol., 2000, 78(11), 912-919.
198. Parkinson, A.; Mudra, D.R.; Johnson, C.; Dwyer, A.; Carroll, K.M. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol. Appl. Pharmacol., 2004, 199(3), 193-209. (Pubitemid 39208721)
199. Villeneuve, J.P.; Pichette, V. Cytochrome P450 and liver diseases. Curr. Drug Metab., 2004, 5(3), 273-282. (Pubitemid 38735781)
200. Rendic, S.; Guengerich, F.P. Update information on drug metabolism systems-2009, part II, summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Curr. Drug Metab., 2010, 11(1), 4-84.
201. D'esposito, F.; Nebot, N.; Edwards, R.J.; Murray, M. Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease. Br. J. Clin. Pharmacol., 2010, 70(3), 400-408.
202. He, S.M.; Yang, A.K.; Li, X.T.; Du, Y.M.; Zhou, S.F. Effects of herbal products on the metabolism and transport of anticancer agents. Expert Opin. Drug Metab. Toxicol., 2010, 6(10), 1195-1213.
203. Mathijssen, R.H.; Verweij, J.; De Bruijn, P.; Loos, W.J.; Sparreboom, A. Effects of St. John's wort on irinotecan metabolism. J. Natl. Cancer Inst., 2002, 94(16), 1247-1249. (Pubitemid 34993875)
204. Smith, P.; Bullock, J.M.; Booker, B.M.; Haas, C.E.; Berenson, C.S.; Jusko, W.J. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy, 2004, 24(11), 1508-1514. (Pubitemid 39426346)
205. Orlando, R.; Padrini, R.; Perazzi, M.; De Martin, S.; Piccoli, P.; Palatini, P. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine. Clin. Pharmacol. Ther., 2006, 79(5), 489-499.
206. Orlando, R.; Piccoli, P.; De Martin, S.; Padrini, R.; Floreani, M.; Palatini, P. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo, effects of liver function. Clin. Pharmacol. Ther., 2004, 75(1), 80-88. (Pubitemid 38130120)
207. Kirchheiner, J.; Roots, I.; Goldammer, M.; Rosenkranz, B.; Brockmoller, J. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs, clinical relevance. Clin. Pharmacokinet., 2005, 44(12), 1209-1225. (Pubitemid 41832564)
208. Brenner, S.S.; Herrlinger, C.; Dilger, K.; Murdter, T.E.; Hofmann, U.; Marx, C.; Klotz, U. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin. Pharmacokinet., 2003, 42(3), 283-292. (Pubitemid 36308065)
209. Mrazek, D.A.; Biernacka, J.M.; O'kane, D.J.; Black, J.L.; Cunningham, J.M.; Drews, M.S.; Snyder, K.A.; Stevens, S.R.; Rush, A.J.; Weinshilboum, R.M. CYP2C19 variation and citalopram response. Pharmacogenet. Genomics, 2011, 21(1), 1-9.
210. Fan, L.; Wang, J.C.; Jiang, F.; Tan, Z.R.; Chen, Y.; Li, Q.; Zhang, W.; Wang, G.; Lei, H.P.; Hu, D.L.; Wang, D.; Zhou, H.H. Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation. Eur. J. Clin. Pharmacol., 2009, 65(4), 403-409.
211. Mohammed Abdul, M.I.; Jiang, X.; Williams, K.M.; Day, R.O.; Roufogalis, B.D.; Liauw, W.S.; Xu, H.; Mclachlan, A.J. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br. J. Pharmacol., 2008, 154(8), 1691-1700.
212. Wang, L.S.; Zhou, G.; Zhu, B.; Wu, J.; Wang, J.G.; Abd El-Aty, A.M.; Li, T.; Liu, J.; Yang, T.L.; Wang, D.; Zhong, X.Y.; Zhou, H.H. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin. Pharmacol. Ther., 2004, 75(3), 191-197. (Pubitemid 38314868)
213. Wang, L.S.; Zhu, B.; Abd El-Aty, A.M.; Zhou, G.; Li, Z.; Wu, J.; Chen, G.L.; Liu, J.; Tang, Z.R.; An, W.; Li, Q.; Wang, D.; Zhou, H.H. The influence of St John's Wort on CYP2C19 activity with respect to genotype. J. Clin. Pharmacol., 2004, 44(6), 577-581. (Pubitemid 38668019)
214. Fan, L.; Zhang, W.; Guo, D.; Tan, Z.R.; Xu, P.; Li, Q.; Liu, Y.Z.; Zhang, L.; He, T.Y.; Hu, D.L.; Wang, D.; Zhou, H.H. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin. Pharmacol. Ther., 2008, 83(3), 471-476. (Pubitemid 351272636)
215. Li, D.; Abudula, A.; Abulahake, M.; Zhu, A.P.; Lou, Y.Q.; Zhang, G.L. Influence of CYP3A5 and MDR1 genetic polymorphisms on urinary 6 beta-hydroxycortisol/cortisol ratio after grapefruit juice intake in healthy Chinese. J. Clin. Pharmacol., 2010, 50(7), 775-784.
216. Zhou, S.F.; Liu, J.P.; Chowbay, B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab. Rev., 2009, 41(2), 89-295.
217. Gorski, J.C.; Vannaprasaht, S.; Hamman, M.A.; Ambrosius, W.T.; Bruce, M.A.; Haehner-Daniels, B.; Hall, S.D. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin. Pharmacol. Ther., 2003, 74(3), 275-287. (Pubitemid 37083103)
218. Yoon, M.Y.; Campbell, A.P.; Atkins, W.M. "Allosterism" in the elementary steps of the cytochrome P450 reaction cycle. Drug Metab. Rev., 2004, 36(2), 219-230. (Pubitemid 38802487)
219. Atkins, W.M. Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 291-310. (Pubitemid 40261807)
220. Kapelyukh, Y.; Paine, M.J.; Marechal, J.D.; Sutcliffe, M.J.; Wolf, C.R.; Roberts, G.C. Multiple substrate binding by cytochrome P450 3A4, estimation of the number of bound substrate molecules. Drug Metab. Dispos., 2008, 36(10), 2136-2144.
221. Shimada, T.; Tanaka, K.; Takenaka, S.; Murayama, N.; Martin, M.V.; Foroozesh, M.K.; Yamazaki, H.; Guengerich, F.P.; Komori, M. Structure-Function Relationships of Inhibition of Human Cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 Flavonoid Derivatives. Chem. Res. Toxicol., 2010.
222. Ahlstrom, M.M.; Ridderstrom, M.; Zamora, I. CYP2C9 structuremetabolism relationships, substrates, inhibitors, and metabolites. J. Med. Chem., 2007, 50(22), 5382-5391.
223. Ware, J.A. Membrane transporters in drug discovery and development, A new mechanistic ADME era. Mol. Pharm., 2006, 3(1), 1-2. (Pubitemid 43331746)
224. Zhang, L.; Huang, S.M.; Lesko, L.J. Transporter-mediated drugdrug interactions. Clin. Pharmacol. Ther., 2011, 89(4), 481-484.
225. Pal, D.; Mitra, A.K. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci., 2006, 78(18), 2131-2145.
226. Weiss, J.; Sauer, A.; Frank, A.; Unger, M. Extracts and kavalactones of Piper methysticum G. Forst (kava-kava) inhibit Pglycoprotein in vitro. Drug Metab. Dispos., 2005, 33(11), 1580-1583. (Pubitemid 41539951)
227. Zhang, J.; Zhou, F.; Wu, X.; Gu, Y.; Ai, H.; Zheng, Y.; Li, Y.; Zhang, X.; Hao, G.; Sun, J.; Peng, Y.; Wang, G. 20(S)-ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo, a case for herb-drug interactions. Drug Metab. Dispos., 2010, 38(12), 2179-2187.
228. Lee, C.K.; Choi, J.S. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats. Pharmacology, 2010, 85(6), 350-356.
229. Kim, R.B.; Wandel, C.; Leake, B.; Cvetkovic, M.; Fromm, M.F.; Dempsey, P.J.; Roden, M.M.; Belas, F.; Chaudhary, A.K.; Roden, D.M.; Wood, A.J.; Wilkinson, G.R. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.Pharm. Res., 1999, 16(3), 408-414. (Pubitemid 29162099)
230. Darwich, A.S.; Neuhoff, S.; Jamei, M.; Rostami-Hodjegan, A.Interplay of Metabolism and Transport in Determining Oral DrugAbsorption and Gut Wall Metabolism, A Simulation AssessmentUsing the "Advanced Dissolution, Absorption, Metabolism(ADAM)" Model. Curr. Drug Metab., 2010.
231. Kindla, J.; Muller, F.; Mieth, M.; Fromm, M.F.; Konig, J. Influenceof Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) onOATP1B1- and OATP1B3-mediated Drug Transport. Drug Metab.Dispos., 2011.
232. Zhou, S.; Lim, L.Y.; Chowbay, B. Herbal modulation of Pglycoprotein.Drug Metab. Rev., 2004, 36(1), 57-104.
233. Patel, J.; Buddha, B.; Dey, S.; Pal, D.; Mitra, A.K. In vitrointeraction of the HIV protease inhibitor ritonavir with herbalconstituents, changes in P-gp and CYP3A4 activity. Am. J. Ther.,2004, 11(4), 262-277.
234. Bhardwaj, R.K.; Glaeser, H.; Becquemont, L.; Klotz, U.; Gupta,S.K.; Fromm, M.F. Piperine, a major constituent of black pepper,inhibits human P-glycoprotein and CYP3A4. J. Pharmacol. Exp.Ther., 2002, 302(2), 645-650. (Pubitemid 34787231)
235. Breidenbach, T.; Kliem, V.; Burg, M.; Radermacher, J.; Hoffmann,M.W.; Klempnauer, J. Profound drop of cyclosporin A wholeblood trough levels caused by St. John's wort (Hypericumperforatum). Transplantation, 2000, 69(10), 2229-2230. (Pubitemid 30395071)
236. Piscitelli, S.C.; Burstein, A.H.; Welden, N.; Gallicano, K.D.;Falloon, J. The effect of garlic supplements on thepharmacokinetics of saquinavir. Clin. Infect. Dis., 2002, 34(2),234-238. (Pubitemid 34028358)
237. Giacomini, K.M.; Huang, S.M.; Tweedie, D.J.; Benet, L.Z.;Brouwer, K.L.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.;Hillgren, K.M.; Hoffmaster, K.A.; Ishikawa, T.; Keppler, D.; Kim,R.B.; Lee, C.A.; Niemi, M.; Polli, J.W.; Sugiyama, Y.; Swaan,P.W.; Ware, J.A.; Wright, S.H.; Yee, S.W.; Zamek-Gliszczynski,M.J.; Zhang, L. Membrane transporters in drug development. Nat.Rev. Drug Discov., 2010, 9(3), 215-236.
238. Guillemette, C.; Levesque, E.; Harvey, M.; Bellemare, J.; Menard,V. UGT genomic diversity, beyond gene duplication. Drug Metab.Rev., 2010, 42(1), 22-42.
239. Volak, L.P.; Ghirmai, S.; Cashman, J.R.; Court, M.H.Curcuminoids inhibit multiple human cytochromes P450, UDPglucuronosyltransferase,and sulfotransferase enzymes, whereaspiperine is a relatively selective CYP3A4 inhibitor. Drug Metab.Dispos., 2008, 36(8), 1594-1605.
240. Wu, J.W.; Lin, L.C.; Tsai, T.H. Drug-drug interactions of silymarinon the perspective of pharmacokinetics. J. Ethnopharmacol., 2009,121(2), 185-193.
241. Wang, Q.; Hao, H.; Zhu, X.; Yu, G.; Lai, L.; Liu, Y.; Wang, Y.;Jiang, S.; Wang, G. Regioselective glucuronidation of tanshinoneiia after quinone reduction, identification of human UDPglucuronosyltransferases,species differences, and interactionpotential. Drug Metab. Dispos., 2010, 38(7), 1132-1140.
242. Mohamed, M.F.; Frye, R.F. Inhibition of intestinal and hepaticglucuronidation of mycophenolic acid by Ginkgo biloba extract andflavonoids. Drug Metab. Dispos., 2010, 38(2), 270-275.
243. Kiang, T.K.; Ensom, M.H.; Chang, T.K. UDPglucuronosyltransferasesand clinical drug-drug interactions.Pharmacol. Ther., 2005, 106(1), 97-132.
244. D'andrea, V.; Perez, L.M.; Sanchez Pozzi, E.J. Inhibition of ratliver UDP-glucuronosyltransferase by silymarin and the metabolitesilibinin- glucuronide. Life Sci., 2005, 77(6), 683-692. (Pubitemid 40726355)
245. Sten, T.; Qvisen, S.; Uutela, P.; Luukkanen, L.; Kostiainen, R.;Finel, M. Prominent but reverse stereoselectivity in propranololglucuronidation by human UDP-glucuronosyltransferases 1A9 and1A10. Drug Metab. Dispos., 2006, 34(9), 1488-1494. (Pubitemid 44285389)
246. Kaji, H.; Kume, T. Regioselective glucuronidation of denopamine,marked species differences and identification of human udpglucuronosyltransferaseisoform. Drug Metab. Dispos., 2005,33(3), 403-412. (Pubitemid 40279941)
247. Zhou, J.; Tracy, T.S.; Remmel, R.P. Glucuronidation ofdihydrotestosterone and trans-androsterone by recombinant UDPglucuronosyltransferase(UGT) 1A4, evidence for multipleUGT1A4 aglycone binding sites. Drug Metab. Dispos., 2010,38(3), 431-440.
248. Ulbricht, C.; Chao, W.; Costa, D.; Rusie-Seamon, E.; Weissner,W.; Woods, J. Clinical evidence of herb-drug interactions, asystematic review by the natural standard research collaboration.Curr. Drug Metab., 2008, 9(10), 1063-1120.
249. Zhou, S.; Gao, Y.; Jiang, W.; Huang, M.; Xu, A.; Paxton, J.W.Interactions of herbs with cytochrome P450. Drug Metab. Rev.,2003, 35(1), 35-98. (Pubitemid 36249785)
250. Li, C.; Lee, M.Y.; Choi, J.S. Effects of silybinin, CYP3A4 and Pglycoproteininhibitor in vitro, on the bioavailability of loratadinein rats. Pharmazie, 2010, 65(7), 510-514.
251. Ohno, Y.; Hisaka, A.; Suzuki, H. General framework for thequantitative prediction of CYP3A4-mediated oral drug interactionsbased on the AUC increase by coadministration of standard drugs.Clin. Pharmacokinet., 2007, 46(8), 681-696. (Pubitemid 47204854)
252. Gurley, B.J.; Swain, A.; Williams, D.K.; Barone, G.; Battu, S.K.Gauging the clinical significance of P-glycoprotein-mediated herbdruginteractions, comparative effects of St. John's wort, Echinacea,clarithromycin, and rifampin on digoxin pharmacokinetics. Mol.Nutr. Food Res., 2008, 52(7), 772-779.
253. Andren, L.; Andreasson, A.; Eggertsen, R. Interaction between acommercially available St. John's wort product (Movina) andatorvastatin in patients with hypercholesterolemia. Eur. J. Clin.Pharmacol., 2007, 63(10), 913-916. (Pubitemid 47387911)
254. Piscitelli, S.C.; Burstein, A.H.; Chaitt, D.; Alfaro, R.M.; Falloon, J.Indinavir concentrations and St John's wort. Lancet, 2000,355(9203), 547-548. (Pubitemid 30088677)
255. Yue, Q.Y.; Bergquist, C.; Gerden, B. Safety of St John's wort(Hypericum perforatum). Lancet, 2000, 355(9203), 576-577.
256. Johne, A.; Schmider, J.; Brockmoller, J.; Stadelmann, A.M.;Stormer, E.; Bauer, S.; Scholler, G.; Langheinrich, M.; Roots, I.Decreased plasma levels of amitriptyline and its metabolites oncomedication with an extract from St. John's wort ( Hypericumperforatum ). J. Clin. Psychopharmacol., 2002, 22(1), 46-54. (Pubitemid 34101292)
257. Eich-Hochli, D.; Oppliger, R.; Golay, K.P.; Baumann, P.; Eap,C.B. Methadone maintenance treatment and St. John's Wort - acase report. Pharmacopsychiatry, 2003, 36(1), 35-37. (Pubitemid 36384633)
258. Schwarz, U.I.; Hanso, H.; Oertel, R.; Miehlke, S.; Kuhlisch, E.;Glaeser, H.; Hitzl, M.; Dresser, G.K.; Kim, R.B.; Kirch, W.Induction of intestinal P-glycoprotein by St John's wort reduces theoral bioavailability of talinolol. Clin. Pharmacol. Ther., 2007,81(5), 669-678. (Pubitemid 46625125)
259. Mai, I.; Stormer, E.; Bauer, S.; Kruger, H.; Budde, K.; Roots, I.Impact of St John's wort treatment on the pharmacokinetics oftacrolimus and mycophenolic acid in renal transplant patients.Nephrol. Dial. Transplant., 2003, 18(4), 819-822. (Pubitemid 36432268)
260. Gurley, B.J.; Swain, A.; Barone, G.W.; Williams, D.K.; Breen, P.;Yates, C.R.; Stuart, L.B.; Hubbard, M.A.; Tong, Y.; Cheboyina, S.Effect of goldenseal (Hydrastis canadensis) and kava kava (Pipermethysticum) supplementation on digoxin pharmacokinetics inhumans. Drug Metab. Dispos., 2007, 35(2), 240-245. (Pubitemid 46148736)
261. Galetin, A.; Gertz, M.; Houston, J.B. Potential role of intestinalfirst-pass metabolism in the prediction of drug-drug interactions.Expert Opin. Drug Metab. Toxicol., 2008, 4(7), 909-922.
262. Galetin, A.; Gertz, M.; Houston, J.B. Contribution of intestinalcytochrome p450-mediated metabolism to drug-drug inhibition andinduction interactions. Drug Metab. Pharmacokinet., 2010, 25(1),28-47.
263. Galetin, A.; Hinton, L.K.; Burt, H.; Obach, R.S.; Houston, J.B.Maximal inhibition of intestinal first-pass metabolism as apragmatic indicator of intestinal contribution to the drug-druginteractions for CYP3A4 cleared drugs. Curr. Drug Metab., 2007,8(7), 685-693. (Pubitemid 47591312)
264. Tachibana, T.; Kato, M.; Watanabe, T.; Mitsui, T.; Sugiyama, Y.Method for predicting the risk of drug-drug interactions involvinginhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica,2009, 39(6), 430-443.
265. Watanabe, A.; Nakamura, K.; Okudaira, N.; Okazaki, O.; Sudo, K.Risk assessment for drug-drug interaction caused by metabolismbasedinhibition of CYP3A using automated in vitro assay systemsand its application in the early drug discovery process. DrugMetab. Dispos., 2007, 35(7), 1232-1238. (Pubitemid 46956447)
266. Wienkers, L.C.; Heath, T.G. Predicting in vivo drug interactionsfrom in vitro drug discovery data. Nat. Rev. Drug Discov., 2005,4(10), 825-833. (Pubitemid 41553963)
267. Luo, G.; Guenthner, T.; Gan, L.S.; Humphreys, W.G. CYP3A4induction by xenobiotics, biochemistry, experimental methods andimpact on drug discovery and development. Curr. Drug Metab.,2004, 5(6), 483-505. (Pubitemid 39534494)
268. Almond, L.M.; Yang, J.; Jamei, M.; Tucker, G.T.; Rostami-Hodjegan, A. Towards a quantitative framework for the predictionof DDIs arising from cytochrome P450 induction. Curr. DrugMetab., 2009, 10(4), 420-432.
269. Tsourounis, C.; Bent, S. Why change is needed in researchexamining dietary supplements. Clin. Pharmacol. Ther., 2010,87(2), 147-149.
270. Huang, S.M.; Temple, R.; Throckmorton, D.C.; Lesko, L.J. Druginteraction studies, study design, data analysis, and implications fordosing and labeling. Clin. Pharmacol. Ther., 2007, 81(2), 298-304. (Pubitemid 46174829)
271. Horig, H.; Marincola, E.; Marincola, F.M. Obstacles andopportunities in translational research. Nat. Med., 2005, 11(7), 705-708.
272. Sabroe, I.; Dockrell, D.H.; Vogel, S.N.; Renshaw, S.A.; Whyte,M.K.; Dower, S.K. Identifying and hurdling obstacles totranslational research. Nat. Rev. Immunol., 2007, 7(1), 77-82. (Pubitemid 46020829)
273. Mao, J.; Mohutsky, M.A.; Harrelson, J.P.; Wrighton, S.A.; Hall,S.D. Prediction of CYP3A Mediated Drug-Drug Interactions UsingHuman Hepatocytes Suspended in Human Plasma. Drug Metab.Dispos., 2011.
274. Lewis, D.F.; Ito, Y. Human cytochromes P450 in the metabolismof drugs, new molecular models of enzyme-substrate interactions.Expert Opin. Drug Metab. Toxicol., 2008, 4(9), 1181-1186.
275. Nakanishi, T.; Shibue, Y.; Fukuyama, Y.; Yoshida, K.; Fukuda, H.;Shirasaka, Y.; Tamai, I. Quantitative time-lapse imaging (QTLI)-based analysis of drug-drug interaction mediated by hepatobiliarytransporter, multidrug associated protein 2, in sandwich-culturedrat hepatocytes. Drug Metab. Dispos., 2011.
276. Ekins, S.; De Groot, M.J.; Jones, J.P. Pharmacophore and threedimensionalquantitative structure activity relationship methods formodeling cytochrome p450 active sites. Drug Metab. Dispos.,2001, 29(7), 936-944. (Pubitemid 32605906)
277. Tomlinson, B.; Hu, M.; Lee, V.W. In vivo assessment of herb-druginteractions, possible utility of a pharmacogenetic approach? Mol.Nutr. Food Res., 2008, 52(7), 799-809.
278. Wu, B.; Morrow, J.K.; Singh, R.; Zhang, S.; Hu, M. Three-Dimensional Quantitative Structure-Activity Relationship Studieson UGT1A9-Mediated 3-O-Glucuronidation of Natural FlavonolsUsing a Pharmacophore-Based Comparative Molecular FieldAnalysis Model. J. Pharmacol. Exp. Ther., 2011, 336(2), 403-413.
279. Broccatelli, F.; Carosati, E.; Neri, A.; Frosini, M.; Goracci, L.;Oprea, T.I.; Cruciani, G. A Novel Approach for Predicting PGlycoprotein(ABCB1) Inhibition Using Molecular InteractionFields. J. Med. Chem., 2011, 54(6), 1740-1751.